Latest Revenue Guidance News

Electro Optic Systems (EOS) reports a surge in contract backlog to $415 million, anchored by a landmark $125 million export order for a high-energy laser weapon. Despite a $34.3 million operating cash outflow in Q3, EOS is poised for growth with new defence contracts and product innovations.

Enlitic, Inc. reported a strong quarter with record cash receipts and contract wins, yet withdrew its revenue guidance due to delayed project completions. The company remains confident in reaching operational cash flow break-even by the end of Q4 FY25.

Bioxyne Limited has reported a record-breaking first quarter for FY26, with revenues soaring 210% year-on-year, driven by strong demand in cannabis products and strategic European market advances.

Ava Risk Group reported a solid start to FY2026 with $9 million in Q1 sales orders and a $7.5 million backlog, underpinning its guidance for a profitable first half.

Fluence Corporation reported a robust 72.9% revenue increase in Q3 2025, driven by a strategic pivot towards higher-margin Smart Product Solutions and recurring revenue streams. The company maintains its full-year guidance despite expecting to finish near the lower end.

TZ Limited reports steady sales growth and new Microsoft contracts in Q1 FY2026, reaffirming its $17–21 million revenue guidance amid improving market conditions.

Cann Group Limited has executed a transformative debt restructure, reducing its $70 million debt by 81% and raising $9 million in fresh capital, setting the stage for a positive EBITDA turnaround in FY26.

Qoria Limited reported a strong start to FY2026, with annual recurring revenue climbing 25% year-on-year and record cash receipts of $46.3 million, prompting an upgrade to its full-year revenue guidance.

EROAD pivots strategically to prioritise ANZ electronic road user charging opportunities, revises FY26 guidance downward, and appoints John Scott as Executive Chair to steer growth.

Aroa Biosurgery delivered a robust September quarter with strong cash flow and record sales of its Myriad product, while reaffirming its FY26 revenue and EBITDA guidance. The company also highlighted a promising US Medicare reimbursement proposal for its Symphony product.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

NRW Holdings has completed its acquisition of Fredon Industries, integrating 2,500 new employees and enhancing its electrical and mechanical services portfolio. The company has updated its FY26 guidance, projecting revenue above $4 billion and underlying EBITA between $255 million and $265 million.